Telomir Pharmaceuticals
TELO
7 hedge funds and large institutions have $337K invested in Telomir Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.27% more ownership
Funds ownership: 0% → 0.27% (+0.27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SEM
Suncoast Equity Management
Tampa,
Florida
|
+$184K |
| 2 |
Citigroup
New York
|
+$134K |
| 3 |
Lido Advisors
Los Angeles,
California
|
+$113K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$113K |
| 5 |
BHWM
Beaird Harris Wealth Management
Dallas,
Texas
|
+$35.3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SEM
1
Suncoast Equity Management
Tampa,
Florida
| $126K | +$184K | +24,391 | New |
|
|
2
Citigroup
New York
| $92.8K | +$134K | +17,748 | New |
|
|
3
Lido Advisors
Los Angeles,
California
| $77.3K | +$113K | +15,000 | New |
|
|
BHWM
4
Beaird Harris Wealth Management
Dallas,
Texas
| $24.1K | +$35.3K | +4,673 | New |
|
5
JP Morgan Chase
New York
| $13.6K | +$19.7K | +2,605 | New |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $3.09K | +$4.53K | +600 | New |
|
|
FIA
7
FNY Investment Advisers
New York
| $77 | +$113K | +14,900 | New |
|
TELO Hedge Fund Activity: Q1 2024 in Review
7 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q1 2024, worth a combined $337K.
Buyers outnumbered sellers: 7 funds opened new TELO positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Suncoast Equity Management, opening a new position worth an estimated $184K.
- 7 institutional investors held Telomir Pharmaceuticals (TELO) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $337K of Telomir Pharmaceuticals stock for Q1 2024.
- 7 funds opened new Telomir Pharmaceuticals positions in Q1 2024 and 0 closed out, a net change of +7 holders.
- The largest Telomir Pharmaceuticals buyer in Q1 2024 was Suncoast Equity Management, an estimated $184K added.
Based on aggregated 13F filings for Q1 2024.